Intersect ENT (NasdaqGM:XENT) - Share price, News & Analysis

XENT fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

XENT Stock Overview

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States.

Rewards

Revenue is forecast to grow 24.17% per year

Risk Analysis

Negative shareholders equity

Currently unprofitable and not forecast to become profitable over the next 3 years

Has less than 1 year of cash runway

Shareholders have been diluted in the past year

Intersect ENT Competitors

Medtronic

NYSE:MDT

US$137.7b

Stryker

NYSE:SYK

US$88.2b

Johnson & Johnson

NYSE:JNJ

US$465.4b

Olympus

TSE:7733

JP¥3.5t

Price History & Performance

Summary of all time highs, changes and price drops for Intersect ENT
Historical stock prices
Current Share Price	US$28.24
52 Week High	US$28.25
52 Week Low	US$15.92
Beta	1.45
1 Month Change	0.89%
3 Month Change	3.33%
1 Year Change	59.91%
3 Year Change	9.42%
5 Year Change	24.13%
Change since IPO	118.58%

Shareholder Returns

	XENT	US Medical Equipment	US Market
7D	1.5%	-2.3%	-2.5%
1Y	59.9%	-15.6%	-10.4%

Return vs Industry: XENT exceeded the US Medical Equipment industry which returned -17.5% over the past year.

Return vs Market: XENT exceeded the US Market which returned -10.8% over the past year.

Price Volatility

Is XENT's price volatile compared to industry and market?
XENT volatility
XENT Average Weekly Movement	0.9%
Medical Equipment Industry Average Movement	10.4%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	2.8%

Stable Share Price: XENT is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 1% a week.

Volatility Over Time: XENT's weekly volatility (1%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2003	433	Tom West	https://www.intersectent.com

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries.

Intersect ENT Fundamentals Summary

How do Intersect ENT's earnings and revenue compare to its market cap?
XENT fundamental statistics
Market Cap	US$954.90m
Earnings (TTM)	-US$168.41m
Revenue (TTM)	US$104.00m

9.2x

P/S Ratio

-5.7x

P/E Ratio

Is XENT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
XENT income statement (TTM)
Revenue	US$104.00m
Cost of Revenue	US$29.25m
Gross Profit	US$74.75m
Other Expenses	US$243.16m
Earnings	-US$168.41m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-4.98
Gross Margin	71.88%
Net Profit Margin	-161.94%
Debt/Equity Ratio	-151.7%

How did XENT perform over the long term?

See historical performance and comparison

Valuation

Is Intersect ENT undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

In this section, we usually try to help investors determine whether Intersect ENT is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Intersect ENT has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.

Future Growth

How is Intersect ENT forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

80.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: XENT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XENT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XENT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XENT's revenue (24.2% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: XENT's revenue (24.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if XENT's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Intersect ENT performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-45.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: XENT is currently unprofitable.

Growing Profit Margin: XENT is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: XENT is unprofitable, and losses have increased over the past 5 years at a rate of 45.3% per year.

Accelerating Growth: Unable to compare XENT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XENT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (19.1%).

Return on Equity

High ROE: XENT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Financial Health

How is Intersect ENT's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: XENT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: XENT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.

Debt to Equity History and Analysis

Debt Level: XENT has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: XENT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XENT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: XENT has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 24.4% each year.

Dividend

What is Intersect ENT current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate XENT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XENT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XENT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XENT's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as XENT has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Healthcare industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure

CEO

Tom West (57 yo)

2.83yrs

Tenure

US$6,275,125

Compensation

Mr. Thomas A. West, also known as Tom, is an Independent Director at Orthofix Medical Inc. since December 2021. He has been President, Chief Executive Officer and Director of Intersect ENT, Inc. since July...

CEO Compensation Analysis

Compensation vs Market: Tom's total compensation ($USD6.28M) is above average for companies of similar size in the US market ($USD3.90M).

Compensation vs Earnings: Tom's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: XENT's management team is considered experienced (2.5 years average tenure).

Board Members

Experienced Board: XENT's board of directors are considered experienced (4.8 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/13 00:00
End of Day Share Price	2022/05/12 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31